the category that includes dronabinol accounted for more statutory health insurance prescriptions than cannabis flower in 2025. Dunbar Pharma is a high potential startup (HPSU) client of Enterprise Ireland, supported through the HPSU Programme in...
health system in the U.S. serving nine million enrolled veterans annually. Proliv Rx received FDA approval in December 2025 as the first and only prescription at-home brain neuromodulation therapy for adults with MDD who have not achieved adequate...
for ENFLONSIA in the European Union (EU) for the same population. ENFLONSIA was approved by the U.S. FDA in June 2025 and by the European Commission in April 2026 for the prevention of RSV LRTD in infants born during or entering their first RSV...
Services (CMS). Retail prescription drug spending is also projected by the CMS to grow an average of 5.7% annually from 2025 through 2034, faster than other major healthcare category. Traditional PBM arrangements can create revenue through spread...
as easily as a glass of iced tea fits into a Texas summer. resG was named one of the Best Foods For Men by Men's Health in 2025. About Resbiotic Nutrition, Inc. ("resbiotic" or "res"): Founded by physician-scientist-entrepreneur Dr. C. Vivek Lal,...
investment: Research and development expenses increased to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses decreased to $2.7 million from $4.0 million and net loss decreased to $5.0 million...
co-prescribing among adult populations and adapt them for CHOP's needs," Bythrow said. Between October 2023 and June 2025, the initiative was implemented in three phases across the health system. The team implemented an EHR-based automated alert...
pneumococcal vaccination series for children and adolescents at increased risk for pneumococcal disease. According to a 2025 study of 2015-2019 CDC ABC surveillance data, including three groups, one of which consisted of children
According to U.S. customs data, peptide imports from China nearly doubled to $328 million in the first three quarters of 2025, fueling a surge of unregulated operators selling research-only chemicals with no quality control or accountability....
through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros....
commercial growth for EVERY: in the first four months of 2026, the company secured annual orders worth 550% of its total 2025 order volume. This surge is driven by strong adoption across B2B retail channels, including national placement in Target...
the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with...
View Research, the global collagen market is expected to reach $26.2 billion by 2033, growing at a CAGR of 11.0% from 2025 to 2033. While collagen supplementation has become one of the fastest-growing segments within wellness and beauty, consumer...
across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2025 were JPY 364 billion with global distribution of products and services in more than 125 countries and regions. For more...
an infected individual may develop COVID-19.6 The U.S. Centers for Disease and Control estimates that between October 1, 2025 and May 23, 2026 there were 3.8-12.4 million new cases in the U.S., resulting in 800,000 – 2.3 million outpatient visits,...
a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which began in December 2025. The milestone: the first patient has been dosed in an investigator initiated trial (IIT) using ImmuXell’s TCR-T cell therapy...
fourth among men,4 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025.4 Historically, 75% of bladder cancer presents as NMIBC.5 In patients with high-risk NMIBC, intravesical BCG remains the...
This latest milestone builds upon the company's landmark first-in-human procedures reported in September and December of 2025. In up to nine-months follow-up of the initial four cases, the RoseDoc platform demonstrates exceptional efficacy, safety...
system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025..
sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with...
